Replies to post #220642 on Biotech Values

[biomaven0]

FGEN has another pipeline HIF-1 drug that would be better suited to post-MI treatment. In that context you want to upregulate VEGF, for example. But they haven't talked about it in years. Some of that is a general decision to publish less and some is simply a focus on their two late-stage drugs.